4.1 Therapeutic indications
Medrone is indicated for conditions requiring glucocorticoid activity such as:-
1. Endocrine disorders
Primary and secondary adrenal insufficiency
Congenital adrenal hyperplasia
2. Rheumatic disorders
Juvenile chronic arthritis
3. Collagen diseases/arteritis
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Rheumatic fever with severe carditis
Giant cell arteritis/polymyalgia rheumatica
4. Dermatological diseases
5. Allergic states
Severe seasonal and perennial allergic rhinitis
Drug hypersensitivity reactions
Allergic contact dermatitis
6. Ophthalmic diseases
Anterior uveitis (iritis, iridocyclitis)
7. Respiratory diseases
Fulminating or disseminated tuberculosis (with appropriate anti-tuberculous chemotherapy)
Aspiration of gastric contents
8. Haematological disorders
Idiopathic thrombocytopenic purpura
Haemolytic anaemia (autoimmune)
9. Neoplastic diseases
Leukaemia (acute and lymphatic)
10. Gastro-intestinal diseases
Tuberculous meningitis (with appropriate anti-tuberculous chemotherapy)
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease.
This study is a long-term, open-label study using NPSP558 for the treatment of adult patients with Hypoparathyroidism.
Long-term testosterone replacement therapy is mainly monitored by trough levels of serum testosterone (S-T), while urinary testosterone (U-T) is used by forensic toxicology to evaluate testosterone doping.
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).